Mutated genes in pancreatic cancer

He, Songbing; Li, Dechun

doi:10.1007/s11670-010-0093-9

Cited by 4 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pancreatic cancer is often difficult to diagnose in the early stages; only 10–15% of patients are eligible for surgical treatment at diagnosis. Current clinical treatments for pancreatic cancer have limited efficacy, highlighting the need for improved treatment strategies to prolong patient survival [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Distribution and Clinical Significance of Th17 Cells in the Tumor Microenvironment and Peripheral Blood of Pancreatic Cancer Patients

Fei

et al. 2011

IJMS

123

View full text Add to dashboard Cite

This study was designed to investigate the distribution of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients, its clinical significance, and the expression profile of Th17 cell-associated cytokines. The percentage of Th17 cells detected by flow cytometry analysis (FACS) was significantly higher in 46 pancreatic tumor tissues (5.28 ± 1.65%) compared with corresponding adjacent normal tissues (2.57 ± 0.83%) (P = 0.031). In addition, the percentage of Th17 cells was significantly higher in stage III-IV tumors than stage I-II tumors (P = 0.039). The percentage of Th17 cells in peripheral blood of 20 pancreatic cancer patients (3.99 ± 1.15%) was significantly higher than 15 healthy volunteers (1.98 ± 0.57%) (P = 0.027). Immunohistochemistry (IHC) was performed to detect IL-17+ cells in 46 pancreatic tumor tissues, as well as expression of CD34 in 24 tumor tissues. IL-17 was shown to mainly locate in cytoplasm, and the frequency of IL-17+ cells in tumor tissues (39/46) was higher than control (29/46). The presence of IL-17+ cells in tumor tissues was associated with tumor, node, and metastasis (TNM) stage, and lymph node metastasis (P = 0.012 and P = 0.009) but not with patient sex, age, tumor size, and histological grade (P > 0.05). Interestingly, distribution of Th17 cells in tumor tissues was positively correlated with microvessel density (MVD) (r = 0.86, P = 0.018). Furthermore, the median survival time of patients with high and low level of IL-17+ cells frequency was 14.5 and 18.5 months respectively (P = 0.023). The serum levels of Th17 cell-associated cytokines, IL-17 and IL-23 in 20 pancreatic patients detected by enzyme-linked immunosorbent assay (ELISA) were 69.2 ± 28.5 pg/mL and 266.5 ± 98.1 pg/mL, respectively, which were significantly higher than 15 healthy volunteers (P = 0.015 and P = 0.02). Moreover, levels of IL-17 and IL-23 were significantly higher in stage III-IV tumors than stage I-II tumors (P = 0.04 and P = 0.036). This study suggests that increase in Th17 cells frequency and its related cytokines levels in pancreatic tumor tissues may indicate involvement in the invasion and metastasis of pancreatic cancer, which may thereby affect patient prognosis. Therefore, Th17 cells and related cytokines may be served as important immune indicators for predicting the prognosis of pancreatic cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Distribution and Clinical Significance of Th17 Cells in the Tumor Microenvironment and Peripheral Blood of Pancreatic Cancer Patients

Fei

et al. 2011

IJMS

123

View full text Add to dashboard Cite

show abstract

“…Pancreatic cancer is often difficult to diagnose in an early stage; only 10-15% of patients are eligible for surgical treatment at diagnosis. Current clinical treatments for pancreatic cancer have limited efficacy, highlighting the need for improved treatment strategies to prolong patient survival (3,4). Implantation of radioactive isotopes for the treatment of pancreatic carcinoma has been used for the past several decades as it can maximize local dose and minimize irradiation of surrounding normal tissue (5 -7).…”

mentioning

confidence: 99%

MicroPET-CT evaluation of interstitial brachytherapy in pancreatic carcinoma xenografts

Wang

Chen

et al. 2013

Acta Radiol

View full text Add to dashboard Cite

show abstract

“…As shown in Fig. 3, the curves described as a exponential (Ln(S(t)/S 0 ) = -k 1 t =-t/τ), indicated that terbium ions occupied the same average coordination environment [13]. The luminescence lifetimes of terbium at excited state ( 5 D 4) in the complexes were determined to be 1045.79 µs and 1172.71 µs, respectively.…”

Section: Fluorescence Spectra and Quantum Yieldsmentioning

confidence: 83%

Enhanced Luminescence of Terbium Complexes with 2,3-Pyrazinedicarboxylate by Y(III) Doping

Wang

Zhang

Kong

et al. 2013

AMR

View full text Add to dashboard Cite

Ten kinds of terbium doped inert yttrium complexes with 2,3-pyrazinedicarboxylate (2,3-pzdc2-) have been synthesized. Characterization results indicate that the complexes have the compositions of Tb (pzdc)1.55H2O and TbxYy(pzdc)1.55H2O (x:y=0.10:0.90; 0.20:0.80; 0.30:0.70; 0.40:0.60; 0.60:0.40; 0.70:0.30; 0.80:0.20; 0.90:0.10). IR spectra show that the lanthanide ions coordinate with the carboxylic oxygen atoms and nitrogen atoms of the ligands. Luminescence spectra show that the Y(III) ions can remarkably increase the luminescent intensities of terbium complexes. And Tb0.7Y0.3(pzdc)1.55H2O exhibits the strongest luminescent emission. Furthermore, the doped lanthanide complexes show longer luminescence lifetimes and higher quantum yields. The enhanced luminescence efficiencies of Tb3+ions in the doped complexes may result from intramolecular energy transfer as well as the decrease of the self-quench of the Tb3+ions induced by the doped Y(III) ions.

show abstract

Mutated genes in pancreatic cancer

Cited by 4 publications

References 43 publications

Distribution and Clinical Significance of Th17 Cells in the Tumor Microenvironment and Peripheral Blood of Pancreatic Cancer Patients

Distribution and Clinical Significance of Th17 Cells in the Tumor Microenvironment and Peripheral Blood of Pancreatic Cancer Patients

MicroPET-CT evaluation of interstitial brachytherapy in pancreatic carcinoma xenografts

Enhanced Luminescence of Terbium Complexes with 2,3-Pyrazinedicarboxylate by Y(III) Doping

Contact Info

Product

Resources

About